Announcements Trials
Browse Landscape

Phase

Phase 2 17Phase 3 5Phase 2/3 2Phase NA 1Phase EARLY_PHASE1 1

Status

Enrolling by invitation 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 4CNS 3Other hematologic neoplasm 2Genitourinary 1

Conditions

Muscle Invasive Bladder Urothelial Carcinoma 1

Interventions

Magnetic Resonance Spectroscopy 13gallium 68 PSMA-11 8Fluorodeoxyglucose F18 5Specimen Handling 4Positron Emission Tomography Computed Tomography 42-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido)pentanedioic acid 4enzalutamide 3Nivolumab 3Ipilimumab 3Interleukin-2 3Biopsy 368Ga-DKFZ-PSMA-11 3pembrolizumab 2pazopanib 2lenvatinib 2bicalutamide 2atezolizumab 2aldesleukin 2acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 2X-Rays 2Standard of Care 2Radiation 2Positron-Emission Tomography 2Paclitaxel 2Oncolytic Virotherapy 2Nephrectomy 2Metformin 2Metastasectomy 2Immunoglobulin G 2Hydroxychloroquine 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase EARLY_PHASE1 × Methotrexate × Genitourinary × Clear all
NCT06204614 2026-05-18

Drug Screening Using IMD in Bladder Cancer

Brigham and Women's Hospital

Phase EARLY_PHASE1 Enrolling by invitation
18 enrolled
Genitourinary

Muscle Invasive Bladder Urothelial Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡